Literature DB >> 15257861

Hypertension management in patients with diabetic nephropathy.

Anthony L McCall1.   

Abstract

Treatment of hypertension, to reverse and delay proteinuria progression and kidney failure, is the primary focus of medical management in patients with diabetic nephropathy. The initial choice for hypertension treatment in those with early nephropathy involves agents that block the renin-angiotensin system. However, it is not clear what the best choices for further drug therapy management are, because there are few data concerning the impact that antihypertensive drug combinations have on hard clinical outcomes, such as preventing the need for dialysis, and death. Patients usually require several drugs for controlling hypertension, which becomes harder to control as nephropathy progresses. In this review, it is suggested that quantitatively tracking proteinuria to guide therapy and a broad focus on the cardiovascular and renal end points are important for best outcomes in patients. Strategies may vary based on stage of disease, comorbidities, and age. Therapies not directed specifically at hypertension may also significantly aid hypertension management in prevention of progressive nephropathy, comorbidities, and mortality.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15257861     DOI: 10.1007/s11906-004-0021-9

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  54 in total

1.  Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study.

Authors:  P Gaede; P Vedel; H H Parving; O Pedersen
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

Authors:  S M Haffner; M P Stern; H P Hazuda; B D Mitchell; J K Patterson
Journal:  JAMA       Date:  1990-06-06       Impact factor: 56.272

3.  Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.

Authors:  Peter Jacobsen; Steen Andersen; Kasper Rossing; Berit R Jensen; Hans-Henrik Parving
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Authors:  Giancarlo Viberti; Nigel M Wheeldon
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

Review 9.  RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease.

Authors:  Jay Lakkis; Wei X Lu; Matthew R Weir
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

10.  Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.

Authors:  G L Bakris; M R Weir; V DeQuattro; F G McMahon
Journal:  Kidney Int       Date:  1998-10       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.